一种结合人淋巴细胞活化基因3(LAG-3)的抗体及其用途

• Format: Patent
• Language: Chinese
• Published: 02.06.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

本发明涉及一种结合人淋巴细胞活化基因3(LAG-3)的抗体及其用途。具体而言，所述抗体或其抗原结合片段包括：(a)包含SEQ ID NO:5的重链CDR1、包含SEQ ID NO:6的重链CDR2和包含SEQ ID NO:7的重链CDR3；以及(b)包含SEQ ID NO:8的轻链CDR1、包含SEQ ID NO:9的轻链CDR2和包含SEQ ID NO:10的轻链CDR3。本发明的抗体特异性识别LAG-3蛋白的同时能够有效阻断MHCII或FGL1与LAG-3分子的结合，具有潜在的抑瘤活性。 The present invention relates to an antibody binding to human lymphocyte activation gene 3 (LAG-3) and an application thereof. Specifically, the antibody or an antigen-binding fragment thereof comprises: (a) a heavy chain CDR1 comprising SEQ ID NO: 5, a heavy chain CDR2 comprising SEQ ID NO: 6, and a heavy chain CDR3 comprising SEQ ID NO: 7; and (b) a light chain CDR1 comprising SEQ ID NO: 8, a light chain CDR2 comprising SEQ ID NO: 9, and a light chain CDR3 comprising SEQ ID NO: 10. The antibody in the present invention can effectively block binding of MHCII or FGL1 to LAG-3 molecules while specifically recognizing LAG-3 protein, and has potential antitumor activity.